TNGX Tango Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNGX

Price (delayed)

$7.61

Market cap

$812.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$783.81M

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million ...

Highlights
Tango Therapeutics's EPS has increased by 12% YoY and by 2.7% QoQ
The company's net income rose by 6% YoY
The gross profit rose by 47% year-on-year but it has declined by 2.6% since the previous quarter
The revenue rose by 47% YoY but it fell by 2.6% QoQ
The equity has decreased by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://tangotx.com
Peers: NWBO

Key stats

What are the main financial stats of TNGX
Market
Shares outstanding
106.72M
Market cap
$812.13M
Enterprise value
$783.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.07
Price to sales (P/S)
19.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.46
Earnings
Revenue
$36.53M
EBIT
-$101.61M
EBITDA
-$95.59M
Free cash flow
-$119.51M
Per share
EPS
-$1.08
Free cash flow per share
-$1.26
Book value per share
$2.48
Revenue per share
$0.39
TBVPS
$4.26
Balance sheet
Total assets
$402.57M
Total liabilities
$149.46M
Debt
$38.92M
Equity
$253.11M
Working capital
$300.6M
Liquidity
Debt to equity
0.15
Current ratio
7.54
Quick ratio
7.35
Net debt/EBITDA
0.3
Margins
EBITDA margin
-261.7%
Gross margin
100%
Net margin
-278.5%
Operating margin
-312.6%
Efficiency
Return on assets
-25.2%
Return on equity
-42%
Return on invested capital
-30.6%
Return on capital employed
-28.5%
Return on sales
-278.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TNGX stock price

How has the Tango Therapeutics stock price performed over time
Intraday
0.26%
1 week
2.28%
1 month
-0.91%
1 year
134.88%
YTD
-23.13%
QTD
-4.16%

Financial performance

How have Tango Therapeutics's revenue and profit performed over time
Revenue
$36.53M
Gross profit
$36.53M
Operating income
-$114.17M
Net income
-$101.74M
Gross margin
100%
Net margin
-278.5%
The gross profit rose by 47% year-on-year but it has declined by 2.6% since the previous quarter
The revenue rose by 47% YoY but it fell by 2.6% QoQ
The net margin has grown by 36% YoY but it has contracted by 4.4% from the previous quarter
The operating margin is up by 30% year-on-year but it is down by 7% since the previous quarter

Growth

What is Tango Therapeutics's growth rate over time

Valuation

What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
3.07
P/S
19.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.46
Tango Therapeutics's EPS has increased by 12% YoY and by 2.7% QoQ
The stock's P/B is 18% more than its last 4 quarters average of 2.6
The equity has decreased by 8% QoQ
The revenue rose by 47% YoY but it fell by 2.6% QoQ

Efficiency

How efficient is Tango Therapeutics business performance
Tango Therapeutics's return on sales has increased by 36% YoY but it has decreased by 4.4% QoQ
The ROE is down by 11% year-on-year
The ROA is down by 6% year-on-year and by 3.7% since the previous quarter
TNGX's ROIC is up by 4.7% YoY but it is down by 4.1% from the previous quarter

Dividends

What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNGX.

Financial health

How did Tango Therapeutics financials performed over time
The total assets is 169% more than the total liabilities
The total liabilities is down by 20% year-on-year
Tango Therapeutics's quick ratio has decreased by 12% from the previous quarter but it has increased by 11% YoY
The debt is 85% less than the equity
The equity has decreased by 8% QoQ
The debt to equity has grown by 7% since the previous quarter but it has declined by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.